California Concierge Doctor’s Xanax Packages: DEA Action After Registration Surrender

The Drug Enforcement Administration’s DEA telemedicine order over a California doctor’s drug packages revoked his controlled-substance registrations and denied pending applications after he had surrendered his registrations. The transaction behind it began with a request for COVID-19 medication packages and an unsolicited offer of Xanax. The doctor supplied the drug without evaluating the recipient or diagnosing a condition that called for it. For someone inside a remote prescribing business, the revealing part is how easily an offer became a shipment while the medical work went undone.

How a COVID-19 Package Came With Xanax

The doctor offered Xanax during a conversation about medication packages for an undercover agent and his family. The agency’s decision describes a concierge medicine program begun at the start of the pandemic, offering telemedicine, home visits and delivery of COVID-19 medication packages to people at risk of developing the disease.

In April 2020, an undercover Federal Bureau of Investigation agent requested six packages. The doctor introduced Xanax into the conversation himself:

At the administrative hearing, the doctor said he offered the drug as a courtesy because the agent seemed anxious. Xanax is a brand name for alprazolam, a Schedule IV controlled substance. A casual offer of an extra medication had put a controlled drug into the package.

The agent then spoke with the doctor’s wife, who also worked as his medical assistant. He told her he had spoken with the doctor, had been approved for the concierge program and could have Xanax. She packed the order, included the drug and shipped it to his home. The doctor testified that he believed he had no further conversations with the agent after the shipment.

That handoff matters. The information passed to the person packing the order was that the doctor had approved it. At the hearing, the doctor admitted he had neither completed a medical evaluation nor diagnosed a condition that warranted the drug. Approval to send the package had taken the place of a medical decision about the recipient.

The criminal guilty plea quoted in the agency’s decision adds another admission about intake. In that plea, the doctor admitted offering Viagra and Xanax without collecting medical information about the agent or his purported family members, after which staff mailed treatment packs containing Xanax.

Why DEA Found the Xanax Dispensing Improper

The Drug Enforcement Administration found that the doctor supplied Xanax without an examination, a medical reason for the drug or a valid prescription. The agency found that mailing the pills did not qualify as direct administration or dispensing without a prescription.

The federal rule the agency applied required a medical reason for the prescription and a doctor acting within ordinary medical practice. California required an appropriate physical examination and a medical reason for prescribing or supplying the drug. The doctor admitted he had done neither. The agency found that he broke California law and acted outside ordinary medical practice. His explanation that the agent seemed anxious left the missing evaluation unanswered.

The prescription issue stood on its own. The investigator testified that he had found no prescription for the Xanax, and the doctor did not argue that one existed. In this transaction, the agency found that mailing the pills satisfied neither requirement: a valid prescription or direct administration or dispensing to the patient.

Even the bottle carried the instruction the transaction lacked. The decision noted that it was marked RX Only.

The intended recipients also reached beyond the name on the medication. The doctor testified that although the Xanax was dispensed in the agent’s name, it was intended for eligible family members too, potentially including a child in an unusual situation. The agency treated the offer and shipment for family use without a prior examination or valid prescription as part of the conduct supporting revocation. The people expected to take the drug had been offered a package without the medical assessment meant to guide their care.

In telehealth, Medicare payment, state medical licensure and federal controlled-substance registration are separate decisions. Here, the Drug Enforcement Administration examined the clinical decisions and shipment to decide whether the doctor could retain his registrations.

Why Surrender Did Not End the DEA Order

The Drug Enforcement Administration continued after registration surrender because two pending registration applications still required a decision, and the agency wanted a final official account for future dealings with the doctor. In a notice dated June 30, 2022, the doctor told the administrative judge he had voluntarily surrendered five registrations. His applications remained pending. Surrender addressed the registrations he already held. Handing those back left the requests for new authority to be decided.

The agency also considered the doctor’s response to the conduct. It found that he had failed to accept responsibility unequivocally, had tried to justify shipping the Xanax and had shown no corrective measures. It rejected his argument that the episode was too limited to warrant revocation. The agency’s decision rested on what the transaction and his response showed about entrusting him with controlled substances.

The final order took effect on January 19, 2023. It revoked the registrations and denied every pending application for registration in California.

What a Telehealth Insider Would Recognize

The evidence in this case connected the offer, the missing clinical evaluation, the staff handoff and the mailed medication. Someone working inside a prescribing service may see one of those steps closely: what information intake collects, what the clinician reviews, what approval staff receive or what ships to the patient.

The Department of Health and Human Services Office of Inspector General’s July 20, 2022 telemedicine fraud alert identifies insufficient patient contact or information and arrangements without expected or practicable follow-up among the features that warrant scrutiny. Those observations make the workflow relevant beyond the person signing an order. Intake and fulfillment employees can know what reached the clinician and what reached the patient. Our whistleblower experts examine those connections with insiders who know how a prescribing business actually operates.

If your information connects skipped evaluations to false claims for government health care payments, our whistleblower experts work with you to build the case around that payment trail. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know How the Medication Got Sent

If you saw medication approved for shipment while patient evaluations were skipped, speak to one of our Whistleblower Experts about how those medications shipped. We build the case with you, bring in healthcare whistleblower lawyers who understand telemedicine prescribing and stay beside you through the decisions that follow.